Overview
Sales of delta-8 THC and other psychoactive cannabinoids that are chemically modified from natural cannabinoids are booming. Sellers claim that these substances are federally legal under the 2018 Farm Act. But are they? This webinar will first delve into the chemistry of these modified cannabinoids, how they are derived, possible safety concerns, and their similarities and differences from delta-9 THC. Speakers will then discuss the legal status of these relatively new cannabinoids under FDA, USDA, and DEA rules, the evolving nature of state bans, and the potential influence on policy discussions about other cannabis products.
Get Access
- +$100 for nonmembers
Internet Explorer and Microsoft Edge are not supported by the checkout process.
Please use Chrome, Firefox, or Safari. If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.
Speakers
Rod Kight, Founder, Kight Law Office and Attorney, Hemp Industries Association
Michael McGuffin, President, American Herbal Products Association
Jonathan S. Miller, Member, Frost Brown Todd LLC and General Counsel, U.S. Hemp Roundtable
Deborah Miran, Consultant, DMiran Consulting
Moderated by Delia Ann Deschaine, Partner, Epstein Becker & Green, PC
ROD KIGHT is a cannabis business law attorney. He represents legal cannabis businesses throughout the world and is editor and chief writer of the Kight On Cannabis law blog (
MICHAEL McGUFFIN is President at the American Herbal Products Association. He was honored in 2010 for over 20 years of dedicated service, having served as the President of the American Herbal Products Association (AHPA) since 1999 and a member of the Board of Trustee’s for 10 years prior. He has been active in the herbal industry since 1974, having owned both retail and manufacturing businesses in this field. A leading expert on dietary supplement regulation, Mr. McGuffin has been published in scholarly and scientific journals, including the Food and Drug Law Journal and Clinical Pharmacology & Therapeutics, and also wrote the highly-lauded publication AHPA’s Annotated Final Rule on Dietary Supplement cGMP (2007). Additionally, Mr. McGuffin served as Managing Editor of AHPA’s Botanical Safety Handbook (1997) and Herbs of Commerce, 2nd edition (2000). He speaks frequently on dietary supplement regulation in the US and abroad. Mr. McGuffin has represented the herbal industry at state and federal hearings on herbal regulatory issues. He has served as a member of FDA’s Food Advisory Committee Working Group on Good Manufacturing Practices for Dietary Supplements (1998-1999), FDA’s Food Advisory Committee’s Dietary Supplements Subcommittee (2003-2005), California’s Office of Environmental Health Hazard Analysis Food Warning Workgroup (2008-2010), and the Advisory Board of the USC School of Pharmacy Regulatory Science Master’s Degree Program. He also serves on the boards of the American Herbal Pharmacopoeia, the American Association of Acupuncture and Oriental Medicine, and United Plant Savers. McGuffin was awarded the Cliff Adler “Heart in Business” award in 1994 and the Nutrition Business Journal Award for Efforts on Behalf of Industry in 2004 and 2012. Mr. McGuffin has been quoted in a variety of news publications such as the New York Times, the Washington Post, US News & World Report and Newsweek and has made appearances on ABC’s Nightline, National Public Radio, and ABC Radio.
JONATHAN MILLER, the Member-in-Charge of Frost Brown Todd’s Washington, DC office, and leads the national law firm’s broad and diverse hemp practice. There are few individuals who have been more influential in the development of the US hemp industry than the US Hemp Roundtable’s General Counsel, Jonathan. Upon helping found the Roundtable (and its sister organization, the US Hemp Authority), Jonathan has served as the industry’s leading advocate for Hemp and CBD legislation on the ground in Congress and in dozens of state legislatures. A recovering politician (the Democrat was elected twice as Kentucky’s State Treasurer), Jonathan has worked across the aisle with leading hemp champions such as US Senate Minority Leader Mitch McConnell on critical legislation, including the 2014 and 2018 Farm Bills. Now he spends his time working with Congress, the White House, the USDA, FDA and DEA to promote policies that advance the industry. Jonathan supports pro-Israel organizations and serves as President of the Robert S. Miller Family Foundation for Justice and Equity.
DEBORAH MIRAN, former commissioner, was a member of the Natalie M. LaPrade Maryland Medical Cannabis Commission from 2013- 2016. While serving on the commission, she was also a member of the executive committee, policy, and research subcommittees, and was chair of the education subcommittee. She was responsible for developing education programs for doctors and patients and was also an integral part of crafting the current regulations. Prior to the commission she was president and founder of Miran Consulting, Inc. There she advised both brand and generic drug makers on the FDA approval process. Ms. Miran was senior director of regulatory affairs for Alpharma, a generic drug manufacturer, where she directed the submission activities for new and abbreviated new drug applications to the FDA. She has spent over 30 years in the US pharmaceutical industry. Ms. Miran received her Bachelor of Science in chemistry from Iowa State University.
Epstein Becker & Green’s Washington, DC, office. Named to the Washington DC Rising Stars list in the area of Food and Drugs (from 2018 to 2020), Ms. Deschaine focuses her practice on advising pharmaceutical and biotechnology clients on a broad range of FDA regulatory matters. In addition, Ms. Deschaine focuses her practice on the federal and state regulation of controlled substances. She defends clients, including pharmaceutical and biotechnology companies, distributors, pharmacies, hospitals, physician groups, academic medical centers, and other researchers, in government investigations and litigation. Prior to joining the firm, Ms. Deschaine served for six years as an attorney for an international law firm in the areas of pharmaceutical and biotechnology law, and two years at a boutique FDA law firm , both in Washington, DC. Before then, she was an Attorney Advisor for the DEA through the Attorney General’s Honors Program, where she received a Performance Award in 2011. She was also a legal intern for Magistrate Judge Susan K. Gauvey of the US District Court for the District of Maryland.Virtual Learning FAQ
Related Content
